Alpha Galactosidase A Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

Alpha Galactosidase A Polyklonal Antikörper für IHC, IP, WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Ratte

Anwendung

WB, IP, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen

2

Kat-Nr. : 15428-1-AP

Synonyme

Alpha D galactosidase A, Alpha galactosidase A, galactosidase, alpha

---

Galerie der Validierungsdaten

• 

  WB analysis of HEK-293 using 15428-1-AP

  WB result of GLA antibody (15428-1-AP, 1:600) with si-Control and si-GLA transfected HEK293 cells..

• 

  WB analysis using 15428-1-AP

  MCF-7 cells were subjected to SDS PAGE followed by western blot with 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 15428-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 15428-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 15428-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of HEK-293 using 15428-1-AP

  IP Result of anti-Alpha galactosidase A (IP:15428-1-AP, 3ug; Detection:15428-1-AP 1:1000) with HEK-293 cells lysate 1800ug.

• 

  IHC staining of human liver cancer using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human liver cancer using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human liver using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human liver using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human liver cancer using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human liver cancer using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of mouse liver using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded mouse liver using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of mouse liver using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded mouse liver using 15428-1-AP (Alpha galactosidase A antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human liver cancer using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 15428-1-AP (Alpha galactosidase A antibody at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human liver cancer using 15428-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 15428-1-AP (Alpha galactosidase A antibody at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: MCF-7-Zellen, HEK-293-Zellen, HeLa-Zellen
• Erfolgreiche IP: HEK-293-Zellen
• Erfolgreiche Detektion in IHC: humanes Leberkarzinomgewebe, humanes Lebergewebe, Mauslebergewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:3000
• Immunpräzipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunhistochemie (IHC): IHC : 1:250-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 1 publications below
• WB: See 1 publications below
• IHC: See 1 publications below

Produktinformation

15428-1-AP bindet in WB, IP, IHC, ELISA Alpha Galactosidase A und zeigt Reaktivität mit human, Ratten

• Getestete Reaktivität: human, Ratte
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: Alpha Galactosidase A fusion protein Ag7609
• Vollständiger Name: galactosidase, alpha
• Berechnetes Molekulargewicht: 49 kDa
• Beobachtetes Molekulargewicht: 46-50 kDa
• GenBank-Zugangsnummer: BC002689
• Gene symbol: GLA
• Gene ID (NCBI): 2717
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

GLA (Alpha-galactosidase A), also named as Melibiase or Agalsidase, belongs to the glycosyl hydrolase 27 family. It catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. The deficient activity of GLA can cause Fabry disease which is an X-linked inborn error of glycosphingolipid metabolis (PMID: 19287194). Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease (PMID: 20398385). In humans, GLA is synthesized as a 50 kDa precursor, which is further processed to a 46 kDa mature form of the protein (PMID: 9883849, 19387866). It also has a homodimer form with the molecular mass of 110 kDa (PMID: 17287429).

Publikationen

Species	Application	Title
human,mouse	WB,IHC	J Extracell Vesicles; Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.; Authors - Joaquin Seras-Franzoso ; KO Validated
human		Orphanet J Rare Dis; Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.; Authors - Wladimir Mauhin

Verwandte Produkte

BTK Polyclonal antibody

21581-1-AP

TIMM8A Polyclonal antibody

11179-1-AP

MYH7-specific Polyclonal antibody

22280-1-AP

Cardiac Troponin T Polyclonal antibody

15513-1-AP

Cardiac Troponin I Polyclonal antibody

21652-1-AP

Myosin Light Chain 2/MLC-2V Polyclonal antibody

10906-1-AP